Blood type susceptibility to SARS-CoV-2 at a tertiary hospital in Accra, Ghana

Pandemics from viral outbreaks, such as that caused by SARS-CoV-2, have significant impacts worldwide. The factors that underlie differential susceptibility to severe COVID-19 outcomes are not fully understood. The role of the ABO blood group in the outcome of SARS-CoV-2 infections remains to be clarified in different populations. This study described the SARS-CoV-2 seroprevalence and examined the association of the ABO blood group with COVID-19 disease among apparently healthy and COVID-19 patients at the Korle Bu Teaching Hospital, Accra. The study involved 277 participants comprising 200 healthy individuals and 77 PCR-confirmed COVID-19 patients with mild or severe symptoms. Anti-SARS-CoV-2 antibody assay (IgM/IgG) was performed, and ABO blood grouping was done on plasma samples using the reverse blood grouping method. Statistical analyses were performed in R for the association of socio-demographic parameters and ABO blood groupings of participants with SARS-CoV-2 infection status. The total SARS-CoV-2 seropositivity was 61.4% (157/277). Most of the participants (245/277, 88.4%) were unvaccinated. Of the 245 unvaccinated individuals, 127 (51.8%) were IgG reactive. A significant association was observed between ABO blood group and COVID-19 disease status. Antigen A participants had a higher probability of symptomatic infection than non-antigen A individuals. Blood group O appeared more protective than other blood types among the participants. Seropositivity was high among the participants studied—vaccinated and unvaccinated. Blood group A is associated with an increased risk of COVID-19, whereas blood group O appears protective. Further studies involving larger sample sizes are required to confirm these findings.